EAVESDROPPING IN HOUSTON

Overheard: Houston experts weigh in on the future of the Space City

The panel of experts discussed the Space City's history — but also its future as a leader in space exploration. Photo courtesy of SpaceCom

Houston's been known as the Space City for about 50 years since "Houston" was the first word spoken from the surface of the moon. But whether or not that nickname will continue to stick was up for debate at a 2019 SpaceCom panel on November 21.

The panel, entitled "Regional Benefits of a Commercial Space Economy: Case Study Houston," the panelists set out to discuss the city's rich history of space exploration, as well as to answer the question of where Houston's space industry is headed.

"We could ask that question in a passive way, but my preference is that here in Houston we ask the question now, answer it, and be very proactive and deliberate about making sure we get the outcome that we want," says Vernon McDonald, senior vice president at KBR and moderator of the discussion.

If you missed the enlightening discussion, here are a few takeaways from the panelists.

"Houston is in this great position to be this beacon to lead entrepreneurs and inspire other regions to explore further."

Rick Jenet, director of the Center for Advanced Radio Astronomy. Jenet, who is based in Brownsville, Texas, is working to develop a vibrant commercial space hub in South Texas. In a lot of ways, the area looks to Houston's history for its development, he says.

"We built a community of engineers and scientists and a workforce that's all vested in the outcome of the human space flight program."

Steve Altemus, president and CEO of Intuitive Machines. The creation of the Johnson Space Center developed generations within the community of scientists and engineers, but, moving forward, Houston has to be intentional about building its talent base. "I'm very passionate about doing that here in Houston," Altemus adds.

"There's a beacon of hope for our community if we can organize around it and attract commercial business here to keep this city the Space City, but redefine ourselves as a commercial space hub."

Altemus says, adding that it's going to take further development, talent, and funds — like what's happening at the Houston Spaceport — to make this transition.

"Over the years, Houston took space for granted. Houston started to focus on the bigger industries that brought in funding and jobs."

Steven Gonzalez, technology transfer strategist at NASA's Johnson Space Center. At the risk of being unpopular, Gonzalez mentions that the city's attention has been diverted from space exploration. However, he adds, there are new initiatives from the Greater Houston Partnership and Houston First that are picking up the slack.

"The answers to Houston delivering on its potential is going to be collaborations — how well we collaborate."

Harvin Moore, president at Houston Exponential. Houston is collaborative, and the city needs to make sure its resources are inclusive as commercial space develops in town.

"I'd like to say that Houston is the birthplace of human space flight, and in 50 years, I'd like to see the city be the leader and the point of the spirit for human exploration internationally and commercially out in mars and beyond.

Altemus responds when asked about the Space City's next 50 years.

"I think what Houston will be most proud of in 50 years is that we played an extremely important role in shaping how Texas leads the world in commercial space exploration."

Jenet, who mentions that there's space exploration innovation happening statewide.

"When you think about what [leading space exploration] company will be here fifty years from now, I don't think it's been created yet. But I would like that company to be here in Houston."

Gonzalez says, adding that the first trillionaire is likely to make his or her fortune in the space industry, and he wants that money here in Houston.

"A lot of our future is not going to be based on what huge companies or government are doing but much more about entrepreneurs."

Moore says, emphasizing the need for developing startup resources in Houston.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News